用基于人工智能的技术来早期检测痴呆症的行为和心理症状:范围审查
Sofia Fernandes1,2,3, Joëlle Rosselet Amoussou4, Carla Gomes da Rocha1
1School of Health Sciences, University of Applied Sciences and Arts Western Switzerland (HES-SO) Valais-Wallis, Chemin de l'Agasse 5, Sion, 1950, Switzerland, 41 58 606 86 17.
JMIR aging
|October 21, 2025
概括
基于人工智能的技术 (AITs) 对早期发现痴呆症 (BPSD) 的行为和心理症状显示出希望. 进一步的研究应该涉及护士,并评估对患者生活质量的长期影响.
科学领域:
- 老年学是指老年学的学科.
- 计算机科学 计算机科学
- 医疗保健技术 技术 医疗保健 技术
背景情况:
- 痴呆症的行为和心理症状 (BPSD) 是常见的,并对患者产生负面影响.
- 基于人工智能的技术 (AIT) 提供了早期BPSD检测的潜力.
- 需要对AIT用于BPSD检测的现有证据进行全面审查.
研究的目的:
- 识别和总结用于痴呆患者早期BPSD检测的AIT.
- 检查医疗保健专业人员的参与,护理角色,护理环境以及评估的BPSD特征.
- 综合目前关于AIT应用在BPSD管理中的证据.
主要方法:
- 根据乔安娜·布里格斯研究所手册进行的范围审查.
- 2025年3月在多个数据库 (MEDLINE,Embase,PsycINFO,CINAHL,科学网,科克伦图书馆,ProQuest) 中进行的搜索.
- 包括在现实世界痴呆症护理环境中用于BPSD检测AIT的初级研究.
主要成果:
- 在选3670篇文章后,包括来自5个国家的12项研究 (2012-2025年).
- AIT主要使用经典的机器学习与来自传感器和可穿戴设备的数据.
- 研究侧重于激动和攻击性;没有一个研究护士在AIT使用中的角色.
结论:
- AITs代表了一个新兴的领域,用于加强医疗保健中的BPSD检测.
- 建议护士积极参与AIT的开发和评估.
- 未来的研究应该专注于AIT的有效性,长期影响和生活质量改善.
更多相关视频
07:31A Computerized Functional Skills Assessment and Training Program Targeting Technology Based Everyday Functional Skills
Published on: February 13, 2020
7.3K
06:46Automated, Long-term Behavioral Assay for Cognitive Functions in Multiple Genetic Models of Alzheimer's Disease, Using IntelliCage
Published on: August 4, 2018
12.7K
相关概念视频
01:30Dementia
515
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
515
01:22Alzheimer's Disease: Treatment
811
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
811
01:26Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K